The Nerve-Tech Name (Nasdaq: AMIX) That Just Crossed The Atlantic With Patent Protection

Picture an interventional suite.

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored The Nerve-Tech Name (Nasdaq: AMIX) That Just Crossed The Atlantic With Patent Protection *Click Here To Get Our Alerts Faster Via SMS* September 30th Greetings Readers, Picture an interventional suite. The arteries glow on the monitor in sharp detail. The nerves wrapped around them, the ones actually carrying the pain or driving the blood pressure, stay invisible. For decades, physicians have treated those nerves by anatomy and educated guesswork. A small team in The Woodlands, Texas, has been building a way to listen to them instead. Last Thursday, that work gained new protection in Europe. Autonomix Medical, Inc. (Nasdaq: AMIX) announced the grant of European Patent No. EP 4 233 700 B1, which covers systems that assess autonomic nerve activity through measurements taken in the eye. The company says the technology may support patient assessment, treatment guidance and procedural feedback across a range of neuromodulation uses. That grant didn't arrive alone. In July, Autonomix reported its portfolio had reached 112 issued or pending patent applications worldwide. A late-August U.S. patent covering feedback-guided neuromodulation then added protection for systems that pair real-time sensing with controlled therapy delivery. The human data is what first caught our eye. In the first phase of its first-in-human pancreatic cancer pain study, responding femoral-access patients saw mean pain scores fall from 7.89 to 3.22 at four to six weeks, a 59.2% improvement on the visual analog scale. A later post hoc analysis reported every responder was o-pioid fr-ee at the three-month follow-up. Regulatory groundwork is moving too. The company has completed its G-L-P preclinical study in porcine models across multiple anatomical targets, and says the data are expected to support its FDA submissions. Behind The Scenes: Inside The Readout When management walked through the G-L-P results in August, AMIX CEO Brad Hauser didn't frame them as a lab exercise. He said the final pathology and lab findings provide “important validation of our platform.” He also cast the milestone as part of the company's shift from preclinical development toward clinical-stage work. A few weeks later, the story moved to Copenhagen. Chief Medical Officer Dr. Robert Schwartz presented two accepted poster abstracts at CIRSE 2026: one on long-term pain mitigation in pancreatic cancer and one on mapping the nervous system with transvascular technology. That's the audience that would actually use a tool like this. The Pivot: From Cancer Pain To Blood Pressure And Beyond Pancreatic cancer pain is the entry point, not the ceiling. In July, Autonomix reported preclinical data from inside the renal arteries, where its catheter detected and localized renal nerve activity and confirmed changes after targeted ablation. Why does that matter? Today's renal denervation procedures for resistant hypertension are performed without direct physiological feedback, so physicians lean on anatomical landmarks. Autonomix wants to add a live nerve signal to that workflow. The boardroom now reflects that ambition. Sandra Cohen Kalter, former Vice President and Chief Regulatory Counsel at Medtronic, joined in September, bringing regulatory experience that includes Medtronic's Symplicity Spyral renal denervation system. Add a new U.S. patent for overactive bladder, a condition the company says affects an estimated 37Mn Americans, and the platform map keeps widening. The backdrop is a sizable, expanding category. MarketsandMarkets projects the global neuromodulation market could reach $10.68Bn by 2030, up from $6.81Bn in 2025. About Autonomix Medical, Inc. Autonomix is a medical device company. Its core is a catheter-based microchip sensing array designed to detect and differentiate neural signals with greater sensitivity than currently available technologies, paired with targeted RF ablation. The company believes the platform could enable transvascular diagnosis and treatment of peripheral nerve disease virtually anywhere in the body. It has no product revenue yet. The regulatory plan, outlined when its G-L-P study began, runs through an IDE and U.S. clinical work supporting a De Novo FDA application. An expansion phase also covers additional visceral cancers beyond the pancreas. More Details And Sources: AMIX Website. AMIX Presentation. 6 Potential Catalysts Putting (Nasdaq: AMIX) On Our Watchlist #1. Fresh European Patent Extends Protection For Eye-Based Nerve Assessment. The newly granted EP 4 233 700 B1 gives (AMIX) European coverage for technology it says may support treatment guidance and procedural feedback. #2. Completed Study Feeds Directly Into Planned FDA Submissions. Management has said data from the finished G-L-P program are expected to support upcoming FDA filings for (AMIX). #3. Human Pain Data Showed Responders Stepping Away From Opioids. Post hoc PoC 1 data reported 100% of responders treated with the (AMIX) system were o-pioid fr-ee at three months. #4. Renal Denervation Adds A Potential Cardiovascular Growth Lane. Preclinical results showed the (AMIX) catheter could sense, localize, and confirm changes in renal nerve activity. #5. Low Float Profile Could Mean Heightened Volatility Ahead. Yahoo Finance lists a float of roughly 886.89K shares for (AMIX), so the potential for heightened volatility may be significant. #6. An Analyst Target Sits Well Above Tuesday’s Close. Maxim Group has pinned a $42 target on (AMIX). From Tuesday’s close, that target represents a potential 950+% upside. The Bottom Line Autonomix Medical, Inc. (Nasdaq: AMIX) has a clear thesis: nerves drive disease, and a catheter that can hear them could make nerve-targeted procedures far more precise. With G-L-P data complete, patents stacking up on two continents and a Medtronic regulatory veteran in the boardroom, AMIX is a name we think belongs on your radar. Pull up the filings, review the data and keep watching for its next FDA update. We’re kicking off coverage on Autonomix Medical, Inc. (Nasdaq: AMIX). Be on the lookout for updates coming soon. Talk again shortly. Sincerely, Kai Parker StockWireNews (Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.) *StockWireNews.com (“StockWireNews” or “SWN” ) is owned by SWN Media LLC, a single member limited liability company. Data is provided from third-party sources and SWN is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile SWN brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between SWN Media LLC and TD Media LLC, SWN Media LLC has been hired for a period beginning on 09/29/2026 and ending on 09/30/2026 to publicly disseminate information about (AMIX:US) via digital communications. Under this agreement, TD Media LLC has paid SWN Media LLC seventeen thousand five hundred USD ("Funds"). To date, including under the previously described agreement, SWN Media LLC has been paid seventy five thousand USD ("Funds"). These Funds were part of the sixty thousand USD funds that TD Media LLC received from a third party named JRZ Capital LLC who did receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither SWN Media LLC, TD Media LLC and their member own shares of (AMIX:US). Please see important disclosure information here: https://stockwirenews.com/disclosure/amix-wkvsi/#details

SWN Media | 4808 NW 2nd Ave Unit #388 | Boca Raton, FL 33431 US Unsubscribe | Constant Contact Data Notice